Exact Mass: 440.2327632
Exact Mass Matches: 440.2327632
Found 201 metabolites which its exact mass value is equals to given mass value 440.2327632
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Tirofiban
C22H36N2O5S (440.23448060000004)
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
3-[2-[[(1S,2R,3S)-3-[4-(Pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid
Nemiralisib
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C78273 - Agent Affecting Respiratory System
linalool-beta-D-glucopyranoside-2O-acetate,6O-tiglate
methyl-[O2,O4-dimethyl-O6-(tetra-O-methyl-beta-D-galactopyranosyl)-xi-D-galactopyranoside]|Methyl-[O2,O4-dimethyl-O6-(tetra-O-methyl-beta-D-galactopyranosyl)-xi-D-galactopyranosid]
C19H36O11 (440.22575059999997)
(3S,4R)-4-([(1S,4aR,6S,8aS)-decahydro-6-hydroxy-5,5,8a-trimethyl-2-methylidenenaphthalen-1-yl]-methoxy)-5-methoxy-3-(methoxycarbonyl)-5-oxopentanoic acid|cryptoporic acid J
C19H36O11_beta-D-Glucopyranoside, 3-ethyl-4-hydroxy-4-methylpentyl 6-O-[(2S,3R,4R)-tetrahydro-3,4-dihydroxy-4-(hydroxymethyl)-2-furanyl]
C19H36O11 (440.22575059999997)
Ala His Ile Thr
Ala His Leu Thr
Ala His Thr Ile
Ala His Thr Leu
Ala Ile His Thr
Ala Ile Thr His
Ala Leu His Thr
Ala Leu Thr His
Ala Thr His Ile
Ala Thr His Leu
Ala Thr Ile His
Ala Thr Leu His
Asp Ile Pro Pro
C20H32N4O7 (440.22708819999997)
Asp Leu Pro Pro
C20H32N4O7 (440.22708819999997)
Asp Pro Ile Pro
C20H32N4O7 (440.22708819999997)
Asp Pro Leu Pro
C20H32N4O7 (440.22708819999997)
Asp Pro Pro Ile
C20H32N4O7 (440.22708819999997)
Asp Pro Pro Leu
C20H32N4O7 (440.22708819999997)
Glu Pro Pro Val
C20H32N4O7 (440.22708819999997)
Glu Pro Val Pro
C20H32N4O7 (440.22708819999997)
Glu Val Pro Pro
C20H32N4O7 (440.22708819999997)
His Ala Ile Thr
His Ala Leu Thr
His Ala Thr Ile
His Ala Thr Leu
His Ile Ala Thr
His Ile Thr Ala
His Leu Ala Thr
His Leu Thr Ala
His Ser Val Val
His Thr Ala Ile
His Thr Ala Leu
His Thr Ile Ala
His Thr Leu Ala
His Val Ser Val
His Val Val Ser
Ile Ala His Thr
Ile Ala Thr His
Ile Asp Pro Pro
C20H32N4O7 (440.22708819999997)
Ile His Ala Thr
Ile His Thr Ala
Ile Pro Asp Pro
C20H32N4O7 (440.22708819999997)
Ile Pro Pro Asp
C20H32N4O7 (440.22708819999997)
Ile Thr Ala His
Ile Thr His Ala
Leu Ala His Thr
Leu Ala Thr His
Leu Asp Pro Pro
C20H32N4O7 (440.22708819999997)
Leu His Ala Thr
Leu His Thr Ala
Leu Pro Asp Pro
C20H32N4O7 (440.22708819999997)
Leu Pro Pro Asp
C20H32N4O7 (440.22708819999997)
Leu Thr Ala His
Leu Thr His Ala
Pro Asp Ile Pro
C20H32N4O7 (440.22708819999997)
Pro Asp Leu Pro
C20H32N4O7 (440.22708819999997)
Pro Asp Pro Ile
C20H32N4O7 (440.22708819999997)
Pro Asp Pro Leu
C20H32N4O7 (440.22708819999997)
Pro Glu Pro Val
C20H32N4O7 (440.22708819999997)
Pro Glu Val Pro
C20H32N4O7 (440.22708819999997)
Pro Ile Asp Pro
C20H32N4O7 (440.22708819999997)
Pro Ile Pro Asp
C20H32N4O7 (440.22708819999997)
Pro Leu Asp Pro
C20H32N4O7 (440.22708819999997)
Pro Leu Pro Asp
C20H32N4O7 (440.22708819999997)
Pro Pro Asp Ile
C20H32N4O7 (440.22708819999997)
Pro Pro Asp Leu
C20H32N4O7 (440.22708819999997)
Pro Pro Glu Val
C20H32N4O7 (440.22708819999997)
Pro Pro Ile Asp
C20H32N4O7 (440.22708819999997)
Pro Pro Leu Asp
C20H32N4O7 (440.22708819999997)
Pro Pro Val Glu
C20H32N4O7 (440.22708819999997)
Pro Val Glu Pro
C20H32N4O7 (440.22708819999997)
Pro Val Pro Glu
C20H32N4O7 (440.22708819999997)
Ser His Val Val
Ser Val His Val
Ser Val Val His
Thr Ala His Ile
Thr Ala His Leu
Thr Ala Ile His
Thr Ala Leu His
Thr His Ala Ile
Thr His Ala Leu
Thr His Ile Ala
Thr His Leu Ala
Thr Ile Ala His
Thr Ile His Ala
Thr Leu Ala His
Thr Leu His Ala
Val Glu Pro Pro
C20H32N4O7 (440.22708819999997)
Val His Ser Val
Val His Val Ser
Val Pro Glu Pro
C20H32N4O7 (440.22708819999997)
Val Pro Pro Glu
C20H32N4O7 (440.22708819999997)
Val Ser His Val
Val Ser Val His
Val Val His Ser
Val Val Ser His
1-(2-(DI-TERT-BUTYLPHOSPHINO)PHENYL)-3,5-DIPHENYL-1H-PYRAZOLE
C29H33N2P (440.23812280000004)
Ifetroban
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
Trans-1-[4-(4-heptylcyclohexyl)phenoxy]-2,4-dinitro benzene
1-N,4-N-bis(4-methylphenyl)-1-N,4-N-diphenylbenzene-1,4-diamine
Methyl-[4-(4-piperidine-1-ylmethyl-phenyl)-cyclohexyl]-carbaminic acid-(4-chlorophenyl)-ester
C26H33ClN2O2 (440.22304280000003)
Nemiralisib
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C78273 - Agent Affecting Respiratory System
3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide
3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide
methyl (1R,9S,10S,11S)-12-(cyclohexanecarbonyl)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide
3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide
3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide
3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide
1-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-phenylurea
1-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-phenylurea
1-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
methyl N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
1-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-phenylurea
1-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-phenylurea
1-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-phenylurea
1-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
methyl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
2-[(2-Hexanoyloxy-3-pentanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[(3-Acetyloxy-2-nonanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-(2-octanoyloxy-3-propanoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium
2-[(3-Butanoyloxy-2-heptanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
Tirofiban
C22H36N2O5S (440.23448060000004)
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
cPA(20:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
methyl (1r,9r,15r,16s,18r,21r)-2-acetyl-4,15-dimethoxy-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate
(1s,3s,4s,6r,8s,9s,10s,11r,14r,15r,17r)-3,4,10,15-tetrahydroxy-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecan-17-yl 2-hydroxypropanoate
(16e)-6-(2-amino-4-methylpentanoyl)-14-hydroxy-2-oxa-6,9,15-triazatetracyclo[16.2.2.0³,⁷.0⁹,¹³]docosa-1(20),14,16,18,21-pentaen-8-one
asebotoxin iii
{"Ingredient_id": "HBIN017048","Ingredient_name": "asebotoxin iii","Alias": "NA","Ingredient_formula": "C23H36O8","Ingredient_Smile": "CC(C(=O)OC1C2CCC3C1(CC(C4(C(C3(C)O)C5C(C4(C)C)O5)O)O)CC2(C)O)O","Ingredient_weight": "440.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1850","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "137117256","DrugBank_id": "NA"}
(2r,3s,4s,5r,6r)-5-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-2-(hydroxymethyl)-6-{[(3r)-3-hydroxyoctyl]oxy}oxane-3,4-diol
C19H36O11 (440.22575059999997)
5,16-dihydroxy-10,21-diisopropyl-7,18-dimethylpentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁵,²⁰]docosa-1,3(12),4,6,8,13,15,17,19-nonaen-11-one
methyl (2z)-2-[(3s,5's,6'r,7's,8'as)-6'-ethyl-2-hydroxy-5'-(2-oxopropyl)-3',5',6',7',8',8'a-hexahydro-2'h-spiro[indole-3,1'-indolizin]-7'-yl]-3-methoxyprop-2-enoate
(4r)-4-{[(1s,4as,8ar)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methoxy}-5-methoxy-3-(methoxycarbonyl)-5-oxopentanoic acid
(10s,21s)-5,16-dihydroxy-10,21-diisopropyl-7,18-dimethylpentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁵,²⁰]docosa-1,3(12),4,6,8,13,15,17,19-nonaen-11-one
[(1e,3s,4r,7e,11r,12r)-3-(acetyloxy)-11-chloro-12-hydroxy-7,11-dimethyl-4-(prop-1-en-2-yl)cyclotetradeca-1,7-dien-1-yl]methyl acetate
C24H37ClO5 (440.23293820000004)
(3r,11r,16as)-11-benzyl-9-hydroxy-6-methyl-3-propyl-3h,4h,8h,11h,14h,15h,16h,16ah-pyrrolo[2,1-c]1-oxa-4,7-diazacyclotetradecane-1,7,12-trione
5-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-2-(hydroxymethyl)-6-[(3-hydroxyoctyl)oxy]oxane-3,4-diol
C19H36O11 (440.22575059999997)